Investigating how HIV proteins affect amphetamine addiction
Official title: The Role of HIV Proteins in Psychostimulant Abuse
Funded at University of Alabama at Birmingham · NIH-11104302 · Data updated 2026-11-12
This study is looking at how HIV might affect the way the brain responds to amphetamines, which could make addiction worse, and it's for people living with HIV and those struggling with amphetamine use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | May 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $751,112 |
| NIH project number | 1R01DA062680-01 |
| Project ID | NIH-11104302 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who also have a history of amphetamine use or addiction.
✕Less likely to help
Patients who do not have HIV or a history of amphetamine use may not benefit from this research.
What this research studies
This research explores the complex relationship between HIV infection and amphetamine use disorder (AUD). It aims to understand how HIV proteins influence the brain's response to amphetamines, potentially worsening addiction behaviors. By studying both animal models and human behaviors, the research seeks to uncover the molecular mechanisms that link HIV and amphetamine use, which could lead to better treatment strategies for those affected. The findings may provide insights into how HIV impacts dopamine function and addiction progression.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for individuals struggling with both HIV and amphetamine addiction.
How similar studies have gone: While the relationship between HIV and addiction has been noted, this specific investigation into the molecular mechanisms is novel and has not been extensively studied.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Galli, Aurelio — University of Alabama at Birmingham
- Study coordinator: Galli, Aurelio
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.